User:Akash Bhadra/Structural Analysis and Development of Notum Fragment Screening Hits
Introduction
Wnt signalling is implicated in processes involved in animal embryonic development, adult tissue homeostasis, and regeneration. [1] As the enzyme Notum can render Wnt inactive, it is a biologically and medically important target. In Structural Analysis and Development of Notum Fragment Screening Hits[2], the authors aim to discover small-molecule inhibitors of Notum, which suppresses Wnt signaling by removing a lipid modification from Wnt proteins. Biological role of the Wnt pathwaySignalling proteins are used by cells during development and adult homeostasis to facilitate communication and coordinate their activities. Wnt is a family of such signalling pathways, which are important as they represent links between normal development and tumorigenesis, and Wn proteins control a wide range of physiological functions, such as vertebrate axis specification, stem cell maintenance, and synaptogenesis. [3] Wnt ligands bind Frizzled receptors and co-receptors (such as LRP5/6) to stabilize β-catenin and direct context-dependent transcriptional programs that control proliferation, differentiation and morphogenesis. [4] Problems in Wnt signalling are associated with various diseases, including cancer, vascular disease, Alzheimer’s disease, and developmental defects. Notum significance in Wnt signallingNotum is a negative regulator in both development and adult tissues. Notum is a secreted carboxylesterase that plays a key extracellular role in shaping Wnt signaling domains. It specifically removes the O-linked palmitoleate from Wnt ligands, a lipid modification required for receptor engagement. By deacylating Wnt proteins, Notum suppresses their signaling capacity, thereby modulating morphogen gradients and restraining Wnt-dependent proliferation. This enzymatic activity was structurally established in work showing how Notum accommodates the Wnt lipid within its catalytic pocket and catalyzes its hydrolysis. As suppression or elevation in Wnt signalling is implicated in disease, Notum inhibition is investigated for therapeutic implementations. In osteoporosis and age-related bone loss, restoring Wnt activity through Notum inhibition has been shown to increase bone formation. In Alzheimer’s disease, where Wnt signaling is reduced, Notum inhibitors promote neurogenesis and progenitor activity. In colorectal cancer, Notum is often overexpressed in APC-mutant tumors, and inhibiting Notum can counteract tumor-driven Wnt dysregulation. Observed effects of Notum inhibition include enhanced bone density, improved neural progenitor responses, and rejuvenation of stem-cell compartments. Notum is suitable for structure-guided drug design as it posses an enzymatic pocket that binds the palmitoleate group of Wnt proteins. This pocket presents multiple sub-regions that fragments or small molecules can occupy. Notum also readily forms high-quality crystals. These features make Notum a strong candidate for crystallographic fragment screening. Screening for Notum binding fragmentsIn the study Structural Analysis and Development of Notum Fragment Screening Hits, the authors used an X-ray crystallographic fragment screen to identify chemical starting points for Notum inhibitor development. A total of 768 datasets were collected, leading to 61 initial candidates, with 59 confirmed fragment hits after filtering. 58 of these fragments bound within the Notum enzymatic pocket, while one fragment, bound at three distinct non-pocket sites. Several fragments clustered in the central pocket region associated with stronger inhibition, including fragments 7, 15, 16, and 24. Fragment 7 (a 1-phenyl-1,2,3-triazole) became a lead and ultimately produced optimized analogues, including an inhibitor with an IC₅₀ of 0.0067 μM. 7BCE is an example from the structural dataset generated from this screen and represents Notum bound to a fragment hit. The results demonstrate the value of fragment-based screening for generating chemically tractable leads and provide a foundation for ongoing Notum inhibitor development.
| ||||||||||||
References
Page made as part of the course BI3323-Aug2025.
